Get Started

Select Your Diagnosis

Multiple Myeloma

Smoldering Myeloma

MGUS

Call us at (888) 828-2206. We'll help answer any questions you may have.
Trials
Centers
Treatments
Create Account

Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)

Overview

Purpose
Details

This is a Phase I, FIH, open-label, dose escalation study evaluating safety and efficacy of UCART targeting CS1 in patients with relapsed or refractory multiple myeloma (MM). The purpose of this study is to evaluate the safety and clinical activity of one infusion of UCARTCS1A and to determine the Maximum Tolerated Dose (MTD).

SparkCures ID	1038
Trial Phase	Phase 1
Enrollment	18 Patients
Treatments	UCARTCS1A
Trial Sponsors	Cellectis S.A.
NCT Identifier	NCT04142619

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

Doctor Criteria

The following criteria is provided for health care professionals.

Inclusion Criteria:

Patients with confirmed diagnosis of active multiple myeloma (as defined by International Myeloma Working Group [IMWG] criteria) who have relapsed after prior lines of therapy.
Eastern Cooperative Oncology Group Performance Status of 0 or 1;
No previous treatment with investigational gene targeting CS1 or chimeric antigen receptor therapy targeting CS1
Adequate organ function, including bone marrow, renal, hepatic, pulmonary, and cardiac function based on the last assessment performed within the screening period.
Other criteria may apply

🤔 Am I Eligible?

Understanding this criteria can be difficult - call us today.

(888) 828-2206 Create My Account